The post Binance Whale Inflows Collapse, Retail Continues Bitcoin Selling- Coinspeaker appeared on BitcoinEthereumNews.com. Key Notes Wholecoiner inflows to BinanceThe post Binance Whale Inflows Collapse, Retail Continues Bitcoin Selling- Coinspeaker appeared on BitcoinEthereumNews.com. Key Notes Wholecoiner inflows to Binance

Binance Whale Inflows Collapse, Retail Continues Bitcoin Selling- Coinspeaker

Key Notes

  • Wholecoiner inflows to Binance have dropped to cycle lows.
  • Large holders are keeping BTC off exchanges instead of selling.
  • Bitcoin saw a CEX inflow of 1,208 coins in the past 24 hours.

Large Bitcoin

BTC
$89 750



24h volatility:
0.5%


Market cap:
$1.79 T



Vol. 24h:
$35.75 B

 holders are moving fewer coins onto Binance, signaling strong holding behavior and potentially reduced sell pressure just when the market needs stability the most.

According to a CryptoQuant analyst, wholecoiner inflows into Binance, the largest cryptocurrency exchange by trading volume, have been seeing a sharp decline since late 2024.


Large holders, with at least 1 BTC, are becoming long-term holders and choosing not to sell, the analyst wrote.

When whales keep their coins off centralized exchanges, such as Binance, which has strong liquidity, it’s often a bullish signal, with near-term downward risk, the CryptoQuant analyst explained.

With less BTC on exchanges, the liquid supply shrinks. This movement could consequently boost the confidence of serious investors with long-term goals.

Coinspeaker reported that Michael Saylor’s Strategy is preparing for another Bitcoin purchase. The Bitcoin treasury company already holds 660,624 BTC, worth roughly $58.5 billion.

Retail Keeps Selling

Despite the declining wholecoiner inflows into Binance, retail investors have been depositing BTC into Binance over the past day.

According to data from CoinGlass, leading CEXs saw a net inflow of 1,208 BTC in the past 24 hours, hinting at a potential selloff.

The short-term selling pressure from smaller investors has been pushing the market into a highly volatile zone. For instance, Bitcoin has been moving between $88,000 and $90,000 over the past 24 hours.

The leading cryptocurrency is currently trading at $89,500, down by nearly 30% from its October all-time high of $126,198.

On the other hand, the zoomed-out chart shows strong confidence from Bitcoin investors. According to Coinglass, CEX platforms recorded a net outflow of 50,927 BTC over the past 30 days, hinting at boosted accumulation.

Moreover, the total number of BTC sitting inside the leading exchanges dropped from 3.44 million on Jan. 26 to 2.49 million at the time of writing.

If the wholecoiner inflows continue to decline steadily, it could potentially support the Bitcoin price and the broader crypto market in the long-term.

next

Disclaimer: Coinspeaker is committed to providing unbiased and transparent reporting. This article aims to deliver accurate and timely information but should not be taken as financial or investment advice. Since market conditions can change rapidly, we encourage you to verify information on your own and consult with a professional before making any decisions based on this content.

Bitcoin News, Cryptocurrency News, News


Wahid has been analyzing and reporting on the latest trends in the decentralized ecosystem since 2019. He has over 4,000 articles to his name and his work has been featured on some of the leading outlets including Yahoo Finance, Investing.com, Cointelegraph, and Benzinga. Other than reporting, Wahid likes to connect the dots between DeFi and macro on his newsletter, On-chain Monk.

Wahid Pessarlay on X

Source: https://www.coinspeaker.com/binance-whale-inflows-collapse-retail-bitcoin-selling/

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$69,013.56
$69,013.56$69,013.56
-0.83%
USD
Bitcoin (BTC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26